A Study to Evaluate ALN-2232 in Participants With Obesity

NCT07463846 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

156

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity

Interventions

DRUG: ALN-2232
DRUG: Placebo
DRUG: Tirzepatide

Sponsor

Alnylam Pharmaceuticals